Other regulated information

We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.

With eyonis® we are disrupting the management of serious diseases such as lung cancer and liver cancer. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis® is currently under development.

Imaging Services for Clinical Trials

Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for biopharma sponsors worldwide.

Learn More

Request a Demo

10/02/2015

Total number of voting rights and number of shares in the capital at 2015/09/30
Download Voting_rights_shares_capital_20150930.pdf
Disclosure of total number of voting rights and number of shares in the capital at September 30th, 2015, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Total number of voting rights and number of shares in the capital at 2015/09/30